[go: up one dir, main page]

WO2008032847A1 - Préparation externe pour la peau - Google Patents

Préparation externe pour la peau Download PDF

Info

Publication number
WO2008032847A1
WO2008032847A1 PCT/JP2007/068013 JP2007068013W WO2008032847A1 WO 2008032847 A1 WO2008032847 A1 WO 2008032847A1 JP 2007068013 W JP2007068013 W JP 2007068013W WO 2008032847 A1 WO2008032847 A1 WO 2008032847A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
apolactoferrin
external preparation
concentration
antibacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/068013
Other languages
English (en)
Japanese (ja)
Inventor
Hiroyoshi Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UP WELL CO Ltd
Original Assignee
UP WELL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UP WELL CO Ltd filed Critical UP WELL CO Ltd
Priority to JP2008534418A priority Critical patent/JPWO2008032847A1/ja
Publication of WO2008032847A1 publication Critical patent/WO2008032847A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to an external preparation for skin. More specifically, the present invention relates to an external preparation for skin containing antibacterial apo-actoferrin. Background art
  • Living organisms are resistant to invasion of microorganisms in the skin by physical methods or by chemical methods such as bactericidal substances or mucus secretion.
  • infectious ability of a bacterium exceeds the resistance of a living body, an infectious disease appears in the living body.
  • infectious symptoms include, for example, acne, atopic dermatitis, and pyoderma.
  • the causative organism for each of these symptoms can be a bacteria that is resident in the skin.
  • Various drugs have been used for the prevention or treatment of such symptoms, most of which are antibiotics or synthetic antibacterials, which have the problem of strong antibacterial but side effects.
  • Lactoferrin is present in body fluids of many mammals, such as milk.
  • colostrum of breast milk contains 5 to 10 g Z L and occupies 30 to 70% of the total protein contained therein.
  • Ratatofurin is an important protein for maintaining and developing infant health, and has recently been shown to have antibacterial and antibacterial effects, and is used in various fields in addition to the food industry. .
  • Lactofurin is an iron-binding glycoprotein with a molecular weight of about 80,00, which binds two irons in one molecule. Lactofurin releases iron under acidic conditions such as pH 2 and becomes apolatatoferrin.
  • Bacteriostatic bacteriostatic Bacteria) Regarding the action it was considered as follows. The chelating action of apolactoferrin deprives the iron necessary for the growth of microorganisms and restricts its growth. For this reason, microorganisms that strongly require iron during growth are subject to the bacteriostatic (antibacterial) action of ratatopherin. Such a bacteriostatic (antibacterial) action of lactoferrin has been considered particularly in the intestinal environment. Thus, the chelating action of apolatatopherin is attracting attention regarding the bacteriostatic (antibacterial) action of ratatopherin. However, the nature of apolactoferrin itself is still unknown.
  • Japanese Patent Application Laid-Open No. Hei 6-2 7 9 3 10 describes that the antibacterial properties against skin pathogenic bacteria and cariogenic bacteria tend to increase by hydrolyzing lactoferrin with acid. . More specifically, various iron-binding ability products are obtained by treating ratatopherin derived from ushi with citrate and adjusting the pH to 3 or less and then treating at high temperature (95 ° C) for 5 minutes to 3 hours. It is described that a product having a lower iron-binding ability has a higher antibacterial effect against skin resident pathogenic bacteria and cariogenic bacteria. Disclosure of the invention
  • An object of the present invention is to provide an external preparation for skin having high antibacterial activity against skin resident bacteria.
  • the present invention provides a skin external preparation containing apolatatophorin, and in this skin external preparation,
  • the iron binding degree of the apolatatopherin is not more than 5%
  • the total cation concentration in the aqueous solution is 5 mm o 1 Z L or less.
  • a skin external preparation having high antibacterial properties against skin resident bacteria is provided.
  • This topical skin preparation is safe and causes no side effects.
  • FIG. 1 is a graph showing the absorbance in an E. coli culture solution when apolactoferrin or lactoferrin obtained by each acid treatment is added at various concentrations.
  • FIG. 2 is a graph showing the absorbance in the E. coli culture solution when apolatatopherin was added together with various concentrations of sodium chloride.
  • FIG. 3 is a graph showing the absorbance in the culture medium of E. coli when various concentrations of apolatatophorin with different iron binding levels are added.
  • FIG. 4 is a graph showing the absorbance in the culture solution of E. coli when sample A, B, or C, which is apolactoferrin having various iron binding degrees and various total cation concentrations, is added.
  • FIG. 5 is a graph showing the absorbance in the culture solution of Staphylococcus epidermidis when sample A, B, or C, which is apolatatoferrin having various degrees of iron binding and various total cation concentrations, is added.
  • FIG. 6 is a graph showing the absorbance in the culture medium of Micrococcus luteu when various concentrations of apolatatoferin or lactoferrin are added.
  • FIG. 7 is a graph showing the absorbance in Candida albicans culture medium when various concentrations of apolatatoferin or ratatopherin were added.
  • FIG. 8 is a graph showing the number of vaccinia colonies per dish when apolatatoferin or lactoferrin is added.
  • FIG. 9 is a graph showing the change in the dandruff score of the subject's scalp before and after the start of the test using ethanol water containing apolactoferrin or ethanol water containing no apolatatopherin.
  • Figure 10 shows the redness of the subject's scalp before and after the start of the test with ethanol water containing apolactoferrin or ethanol water without apolatatopherin. It is a graph which shows the change of a spot score.
  • the external preparation for skin of the present invention contains apocyclic ferrin.
  • Apolactoferrin is a glycoprotein molecule in which the iron bound in the lactoferrin molecule is released.
  • Apolatopherin used in the present invention is not particularly limited as long as it has the following properties.
  • apolatatopherin has an iron bond degree in the molecule of 5% or less, preferably 4% or less, more preferably 3% or less.
  • the degree of iron binding refers to the ratio of the number of moles of iron to the number of moles of apolatatophorin.
  • the degree of iron binding can be determined by measuring the absorbance of apolactoferrin by spectroscopic analysis, or by directly measuring the amount of iron in aporataferin by atomic absorption spectrometry or ICP spectroscopic analysis. .
  • the degree of iron binding refers to a value obtained by dissolving an apo-ferferin powder in pure water to obtain an lw / v% solution, and measuring this with an absorbance of 470 ⁇ m.
  • the apolactoferrin in the present invention has a total cation concentration of 5 mm o 1 ZL or less when an aqueous solution containing apolatatopherin at a concentration of 1 w / v% is prepared.
  • To determine the total cation concentration dissolve the apolactoferrin powder in 0.1 N hydrochloric acid to prepare a 0.1 lw / v% solution, and measure the amount of each cation by atomic absorption spectrophotometry. Obtain the concentration of each cation by adding the values.
  • the total cation concentration may correspond to the salt (ion) contained as impurities in the apolatatopherin powder.
  • the total cation concentration is preferably 3. Ommo 1 / L or less, more preferably 1. Ommo 1 ZL or less.
  • Apolatoferrin can be usually produced by adjusting the pH of an aqueous solution containing ratatopherin to the acidic side to dissociate the divalent iron ions of the ratatophorin molecule.
  • Lactoferrin the raw material for Apolata tofrin, is separated and purified from mammalian secretions such as milk (eg, milk) or processed milk products such as skim milk and whey (eg, whey) (for example, adsorbed on cation exchange resin) And then desorbing with a high-concentration salt solution, separation method by electrophoresis, separation method using affinity chromatography, etc.). Furthermore, various cells obtained by gene recombination (including microorganisms, plant cells, animal cells, insect cells, etc.), plants, animals and the like may be used.
  • Ratatopherin may be commercially available as a pharmaceutical, a reagent, or the like. Ratatofurin is preferably derived from natural products.
  • Whey obtained as a by-product generated when producing a dairy product (eg, cheese, casein, etc.) from cow's milk or skim milk can be suitably used as a source of ratatopherin.
  • a dairy product eg, cheese, casein, etc.
  • Apo-actoferrin can be preferably produced, for example, by adding an acid to the liquid when ultrafiltration of the ratatopherin-containing liquid is carried out to dissociate iron ions bound to ratatofurin.
  • the acid that can be used here include citrate, hydrochloric acid, phosphoric acid, malic acid, or oxalic acid (0.4 M or more), and citrate is preferred.
  • apolatatoferin is composed of, for example, bipolar membranes and force thione exchange membranes, which are composite ion exchange membranes having a structure in which a cation exchange membrane and an anion exchange membrane are bonded to each other.
  • the use of an electrodialyzer having a partitioned acid chamber and a base chamber can also be suitably produced. In this case, hydrochloric acid produced during the manufacturing process using an electrodialyzer is used as the acid.
  • the acidic side to be regulated The pH is preferably 0.5 to 3.0, more preferably 1.5 to 2.5.
  • the pH is near neutral (eg 5.5)
  • the antibacterial activity of the resulting apolatatoferin may be weak.
  • As a pH adjuster for an aqueous solution containing ratatopherin not only the above-mentioned acids but also phthalic acid, glycine and the like can be used. These pH adjusters are added to an aqueous solution containing ratatoferrin in an amount appropriate for adjusting its pH to the above value.
  • the temperature at which the pH of the aqueous solution containing ratatopherin is adjusted to the acidic side is preferably not high in consideration of protein denaturation. Usually, it is 5 to 60 °, more preferably 15 ° to 35 ° C., and even more preferably room temperature.
  • the specific production of apolatatopherin in the present invention will be described in detail in the following preparation examples, but the production method of aporaltophorin is not limited thereto.
  • the apoloratoferrin in the present invention can also be obtained by modifying a commercially available apolactoferrin so as to have the above iron binding degree and total cation concentration.
  • Apolata topherin can usually be obtained in the form of an aqueous solution.
  • the external preparation for skin of the present invention is prepared using apolar lactin, it may be used in the form of an aqueous solution or in a powdered form after removing the solvent. (External preparation for skin)
  • the amount of apolatatopherin contained in the external preparation for skin of the present invention is not particularly limited because it varies depending on the dosage form.
  • the external preparation for skin of the present invention further improves the appearance, feeling of use and storage stability. Therefore, if necessary, it may contain bases and additives usually used by those skilled in the art for external preparations for skin. Furthermore, various auxiliary agents can be added for the purpose of further enhancing or supplementing the function of the external preparation of the present invention.
  • Examples of the base include glycerol, ethanol, paraben, or butylene glycol.
  • Examples of the additive include excipients (such as dextrins), fragrances, pigments, preservatives (such as parabens), and thickeners.
  • excipients such as dextrins
  • fragrances such as ethanol
  • pigments such as pigments
  • preservatives such as parabens
  • thickeners such as dextrins
  • Silicon polymers acrylic polymers, carboxyvinyl polymers, etc.
  • chelating agents EDTA, etc.
  • sweeteners saccralose, etc.
  • refreshing agents menthol, etc.
  • antiseptic / antifungal agents phenoxyethanol, etc.
  • auxiliary agents examples include other medicinal ingredients and other oils (unsaturated fatty acids such as linoleic acid, linolenic acid, palmitic acid, DHA, EPA, and derivatives thereof, linseed oil, coconut oil, jojoba oil, olive oil, etc.
  • oils unsaturated fatty acids such as linoleic acid, linolenic acid, palmitic acid, DHA, EPA, and derivatives thereof, linseed oil, coconut oil, jojoba oil, olive oil, etc.
  • moisturizers collagen or its degradation products, collagen-like peptides contained in force lot extract, etc.
  • Soy peptides amino acids
  • mucopolysaccharides such as hyaluronic acid
  • amino sugars such as chondroit
  • the external preparation for skin of the present invention can take any form applicable to the skin.
  • the dosage form of the external preparation for skin of the present invention can be, for example, a lotion, emulsion, gel, cream, ointment, powder, granule, tablet or the like.
  • the external preparation of the present invention can be used as cosmetics, pharmaceuticals, quasi drugs, toiletries and the like. These contain components usually used by those skilled in the art, if necessary, and can be prepared according to methods usually used by those skilled in the art.
  • cosmetics for example, makeup for cleaning It can also be used as cosmetics, basic cosmetics, finishing cosmetics, and hair cosmetics.
  • cleansing cosmetics include facial cleansers, stone trials, and body shampoos.
  • Examples of basic cosmetics include lotions, cosmetic creams, emulsions, and packs.
  • Examples of finishing cosmetics include foundation, white powder, lipstick, lip gloss, scarlet, and eye shadow.
  • Examples of hair cosmetics include chamboo, hair rinse, treatment, and styling agent. ⁇ ⁇ It can also be used for shaving agents, hair removal agents, depigmenting agents, etc. It can also be included in a sheet for wiping (for example, a wet tissue or a type of wiping paper).
  • Examples of pharmaceuticals include hair restorers, aqueous ointments, oily ointments, ships, and gels.
  • Apolata topherin can be added to, added to, or incorporated into a topical skin preparation according to procedures commonly used by those skilled in the art. For example, after pre-dissolving in a solvent such as water or alcohol, mixing with other ingredients, or stirring and mixing with other ingredients as a powder, add, compound or include in a skin external preparation. obtain.
  • a solvent such as water or alcohol
  • the external preparation for skin of the present invention is in the form as described above, and can be administered or applied to an individual according to the means usually used for administration or application in that form (for example, application, rubbing, spraying).
  • the external preparation for skin of the present invention can be effective against skin resident bacteria.
  • fungus eg; J "3: Staphylococcus ⁇ (Staphylococcus epidermidis, Staphylococcus aureus, etc.), Micro coccus i / ⁇ (Micrococcus luteu, etc.), Streptococcus ⁇
  • Examples include Pityrosporumfe Candida genus (Candida albicans etc.), Propionibacteriumfe (Propionibacterium acnes etc.), Malassezia genus (Malassezia furfur etc.), Echerichia coli (Escherichia coli) etc.
  • the topical skin preparation of the present invention reduces unpleasant odor (deodorant action) It may have effects such as improvement (including anti-dandruff), prevention of acne, alleviation of atopic dermatitis, prevention of dermatitis (including pyoderma).
  • the external preparation for skin of the present invention is excellent in skin moisture retention, and is suitable for daily use as a product such as cosmetics and toy retail products.
  • LOV low fiber module: membrane inner diameter 0.8 mm, effective membrane area 4 lm 2 , membrane material: polyacrylonitrile
  • Microza UF Lab Testing Machine LX-22001; Asahi Kasei Chemicals Corporation
  • apolactoferrin was produced as follows.
  • apolata topherin 10 kg of a 5 Omg / mL ratatopherin (Fontera; iron binding degree of about 20%) solution was used.
  • lactoferrin was treated with any of the following acids: 0.1 M citrate, 0.1 M lactic acid, 0.1 M hydrochloric acid, 0.1 M malic acid, 0.1 M acetic acid, or 0. 4M acetic acid.
  • the rato-ferrin solution was put into the supply tank of the apparatus, circulated for 10 minutes, and then circulated in the reverse direction for 5 seconds to concentrate the solution.
  • the pressure at the inlet and outlet of the UF membrane and the circulating fluid flow rate were set to 0.12 Mpa, 0.08 Mpa, and 15 LZ, respectively. This operation was repeated until the non-permeate concentrate was halved (this is one round).
  • the citrate solution was put into the tank, and the same operation as above was performed for two rounds.
  • 8 ⁇ ⁇ cm or more of pure water was put into the tank, and the above operation was performed for 5 rounds to remove the acid remaining in the non-permeated concentrate.
  • the temperature of the circulating fluid is Throughout the manufacturing process, it was in the range of 10-28 ° C and the pH was 2-3. A concentrated solution of 4 O kg was obtained by the above production process. The concentrated solution was then freeze-dried to obtain 9.5 g of white powder.
  • BIOXYTECH registered trademark
  • EIA TM OXIS International Inc. USA / Oregon
  • the powder obtained by each acid treatment was apolactoferrin and the purity of apolata toferin It was determined by performing antibody quantification using.
  • the purity of apollatoferrin was as follows: 93% for 0.1 M taenoic acid, 94% for 0.1 M lactic acid, 96% for 0.1M hydrochloric acid, 9 for 0.1M malic acid. 1%, 9 1% with 0.1M acetic acid, 91% with 0.4M acetic acid.
  • the iron binding degree of the powder obtained by each acid treatment was dissolved in pure water so as to have a concentration of lw / v%, and then the amount of iron bound to apolitoferrin was determined as the absorbance at 470 nm. It was determined by measuring with.
  • Table 1 shows the degree of iron binding of the obtained aporatopherin.
  • Example 1 Apolatoferin antibacterial test using E. coli
  • E. coli (NBRC 3972) purchased from the Biotechnology Headquarters, Biotechnology Headquarters, Biotechnology Headquarters, National Institute of Technology and Evaluation, E. coli (NBRC 3972) is subcultured in 5 mL of S CD bouillon (Nissui Pharmaceutical Co., Ltd.) Stored in culture (liquid). 50 ⁇ L of this stored E. coli solution was inoculated into 5 mL of SCD broth and cultured for 16 hours at 30 ° C. in a shaking water bath (preculture). The pre-cultured bacterial solution was diluted with sterile water to prepare 10-fold serial dilutions up to 10 7 -fold.
  • FIG. 1 is a graph showing the absorbance in an E. coli culture solution when apolatatophorin or ratatopherin obtained by each acid treatment was added at various concentrations.
  • the horizontal axis indicates the concentration of apolatatoferin or ratatopherin (%) (w / v) in the culture medium.
  • the vertical axis represents the absorbance, and the lower the absorbance, the smaller the number of viable bacteria, that is, the higher the antibacterial activity.
  • antibacterial action was not seen with ratatofurin, whereas apolatatophorin showed antibacterial action with increasing concentration.
  • the antibacterial effect of apolactoferrin obtained by treatment with citrate was most excellent.
  • FIG. 2 is a graph showing the absorbance in the culture solution of E. coli when various concentrations of apolactophorin with different iron binding levels are added.
  • the horizontal axis indicates the concentration of apolactoferrin (%) (w / v), and the vertical axis indicates the absorbance.
  • the lower the absorbance the smaller the number of viable bacteria, that is, the higher the antibacterial activity.
  • lactoferrin whose iron binding degree was 19.8%, did not show any decrease in absorbance and no antibacterial action was observed.
  • apolata toporin with an iron bond degree of about 4% or less (iron bond degree 4.09%, iron bond degree 2.95%, iron bond degree 2.2%, iron bond degree 1.66%, and iron At a binding degree of 1.0 4%), sufficient antibacterial activity was observed even in an aqueous solution containing apolatapherin at a concentration of 5 w / v%.
  • Example 1 In the antibacterial test of Escherichia coli of Example 1 above, the influence of salt was examined using citrate-treated apolatatophorin. The antibacterial activity was examined according to the same procedure as in Example 1 except that sodium chloride was added to the lw / v% citrate-treated apolactoferrin solution so as to have various ion concentrations.
  • FIG. 3 is a graph showing the absorbance in an E. coli culture solution containing various concentrations of sodium chloride and 2. Ow / v% apolar lactin.
  • the horizontal axis indicates sodium chloride concentration (mmo 1 / L), and the vertical axis indicates absorbance.
  • the antibacterial action decreased as the salt concentration increased. Therefore, it is understood that the amount of salt that can be mixed as impurities in the apopherophine powder affects the antibacterial properties.
  • the amount of such salt is desirably 5 mm o 1 / L or less for all ions when 1% solution of apolatatopherin is used.
  • the total cation concentration of apolatatophorin having an iron binding degree of 2.95% obtained in Preparation Example 2 was determined.
  • 0.1N hydrochloric acid to lyophilized powder of apolactoferrin to prepare 0.1.lw / v% apolactoferrin solution and measuring Na, K :, Ca, Mg, and Cu by atomic absorption spectrophotometry.
  • the concentration of each of these cations was determined, and the total was obtained as the total cation concentration.
  • the total cation concentration of commercial ratatofurin and apolatatophorin was also determined. The results are shown in Table 3.
  • Apolatofurin with a degree of iron binding of 2.95% obtained in Preparation Example 2 had a total cation concentration of 5 mm o 1ZL or less.
  • the absorbance decreased to a certain level or more even though the iron binding degree was 5% or less.
  • the aporal ferrin has a total cation concentration exceeding 5 mm o 1ZL. Therefore, it was considered that both iron binding degree and total cation concentration of apolatatopherin powder affect antibacterial properties.
  • Example 3 the antibacterial activity of apolatatopherin having an iron binding degree of 5% or less and a total cation concentration of 5 mmo 1 / L or less was further examined.
  • the following three types of apo-lactoferrin were used: Sample A (Aporatatophorin commercially available: 4.39% iron binding, 14.7 m total cation concentration) mo l / L); Sample B (Sample A was retreated at a temperature of 25 ⁇ 1 ° C and pH 2.6 according to the method of Preparation Example 1: iron binding degree 3.89%, total cation concentration 4.5 m mo l / L); and Sample C (apolatatophorin obtained in Preparation Example 2 above: degree of iron binding 4.56%, total cation concentration 4.4 mmol ZL).
  • Antibacterial activity was tested using Escherichia coli and Staphylococcus epidermidis (NBRC 3972 and NBRC 13889, respectively, obtained from the National Institute for Biotechnology, Biotechnology Headquarters, NBRC 3972 and NBRC 13889, respectively) The procedure was the same as in Example 1 except that. Staphylococcus epidermidis is a skin-resident bacterium that causes odor. The final concentration of apolatatophorin was 2 OmgZmL.
  • Figures 4 and 5 show the graphs showing the absorbance in the culture solution of Escherichia coli and Staphylococcus epidermidis when samples A, B, and C are added, respectively.
  • the vertical axis represents the absorbance, and the lower the absorbance, the smaller the viable count, that is, the higher the antibacterial activity.
  • Sample A which has an iron binding degree of 5% or less but a total cation concentration of more than 5 mm o 1 / L, showed little difference in absorbance compared to the culture medium without addition of apolatatoferrin.
  • Samples B and C which have an iron binding degree of 5% or less and a total cation concentration of 5 mm o 1 / L, are compared with the culture medium without the addition of apolactoferrin.
  • the absorbance was low and it showed good antibacterial properties.
  • the antibacterial activity against bacteria belonging to the genus Micrococcus was examined for the apolatatophorin having an iron binding degree of 2.95% prepared in Preparation Example 2 above.
  • apolatatophorin having an iron binding degree of 2.95% prepared in Preparation Example 2 above.
  • commercially available ratatopherin manufactured by Fontera
  • Micrococcus bacteria may be skin resident bacteria involved in the development of unpleasant odors.
  • the test is Micrococcus The procedure was the same as in Example 1 except that luteu (NBRC 13867: Independent Administrative Institution ⁇ National Institute of Product Evaluation Technology Biotechnology Logistics Division (National Biogenetic Resource Division) (NBRC)) was used.
  • FIG. 6 is a graph showing the absorbance in the culture medium of Micrococcus luteu when various concentrations of apolatatophorin (Apo-Lfn) or lactoferrin (Lfn) are added.
  • the horizontal axis shows the concentration of apolatatoferin or lactoferrin added (%) (w / v), and the vertical axis shows the absorbance.
  • the lower the absorbance the smaller the number of viable bacteria, that is, the higher the antibacterial activity. From Fig. 6, it was also observed that lactoferrin did not show much antibacterial effect in bacteria of the genus Micrococcus, whereas apo lactoferrin showed antibacterial action as the amount of addition increased.
  • Example 6 Antibacterial test of apolatatopherin against Candida spp.
  • Commercially available Ratatov ⁇ Rin (manufactured by Fontera) was used as the contrast.
  • Candida bacteria can contribute to dermatitis.
  • the test is Candi da albicans (NBRC 1594: Independent Administrative Law, Biotechnology Division, Biotechnology Headquarters, Biotechnology Headquarters)
  • Example 1 Example 1 (Available from (NBRC)), and YM broth (Nippon Betaton Dickinson Co., Ltd.) was used as the growth medium for this bacterium, and the culture conditions for preculture and main culture were 24 hours at 24 ° C. Except for this, the same procedure as in Example 1 was performed.
  • FIG. 7 is a graph showing the absorbance in the Candida albicans culture medium when various concentrations of apolactoferrin (Apo-Lfn) or lactoferrin (Lfn) were added.
  • the horizontal axis is the concentration of apolatatoferin or ratatopherin added
  • Example 7 Antibacterial test of apolatatoferrin against Propionibacterium acnes
  • the antibacterial activity against acne bacteria was examined for the apolactoferrin having an iron binding degree of 2.95% prepared in Preparation Example 2 above.
  • commercially available ratatofrin manufactured by Fontera
  • Acne is a skin-resident bacterium that causes acne.
  • Propionibacterium acnes manufactured by THE VAN Kampen Group, Inc.
  • a liquid medium S CD Bouillon Nasui Pharmaceutical Co., Ltd.
  • apolactoferrin or ratatopherin was mixed with the liquid medium so that their concentration was 2 w / v%.
  • the cells were cultured for 3 days under anaerobic conditions, and the bacteria were diluted 10 times and transferred to SCD agar medium (Nissui Pharmaceutical Co., Ltd.). Furthermore, the cells were cultured for 3 days under anaerobic conditions, and the number of colonies formed was counted. The number of colonies was determined by averaging 10 dishes.
  • FIG. 8 is a graph showing the number of Acne colonies per dish when apolatatoferin or ratatopherin is added. Compared with the addition of lactoferrin, which was the control group, the number of colonies was smaller when apolactoferrin was added, and the antibacterial activity of apolactoferrin was also confirmed against akune bacteria.
  • Malassezia is a skin resident yeast that causes seborrheic dermatitis that can cause dandruff hair loss.
  • YM liquid medium manufactured by Difco
  • the YM liquid medium is adjusted to pH 5.6 with hydrochloric acid before adding olive oil, and the medium is adjusted to 10 OmL.
  • Olive oil (10 g) was added.
  • 1 platinum loop suspension of slant culture was suspended in 5 O mL of this medium to obtain a McFarland 2 suspension (about XI 0 8 ). Using this suspension as a stock solution, 10-fold, 100-fold and 100-fold dilutions were prepared, and these were used as test bacterial solutions.
  • a 10% (w / v, lOOmg / mL) solution is prepared by dissolving the iron binding degree 2.95% prepared in Preparation Example 2 above in distilled water, and then a 0.45 / zm solution. Sterile filtered with a filter. Then, it was diluted to 4% and 2% (both w), and these were used as sample solutions.
  • the sample solution 500 ⁇ L and the bacterial cell suspension 500 ju ju L were added to the 24-well plate tool. Sterile water was used as a blank. For this reason, the concentration of apolatatophorin in each test group is diluted 2-fold to 5%, 2%, and 1% (all are w-8) as shown in the table below.
  • Figure 5 and Figure 10 show the results of dandruff scoring and scalp erythema determination, respectively.
  • the vertical axis shows the dandruff score shown above, and the horizontal axis shows the course before and after the test.
  • the black circles represent the results for ethanol water containing apolatatopherin
  • the white circles represent the results for ethanol water not containing apolatatopherin.
  • the vertical axis shows the score of erythema shown above, and the horizontal axis shows the course before and after the test.
  • black circles represent the results of ethanol water containing apolactoferrin
  • white circles represent the results of ethanol water not containing apolatapherin.
  • Apolactoferrin is expected to have a skin moisturizing effect as well as its antibacterial properties.
  • the reagent was diluted in distilled water by a micro liquid dilution method using a microtiter, and the concentrations of the reagent were changed to prepare an apolatatophorin solution and a concomitant reagent solution. Both the apolatatopherin solution and the concomitant reagent solution were prepared so as to have a final concentration of 2 w / v%, and diluted sequentially. 10 4 to 10 5 cfu / m E. coli (NBRC 3972: Incorporated Administrative Agency ⁇ National Institute of Technology and Evaluation Technology Biotechnology) (Obtained from the Division of Biological and Genetic Resources (NBRC)) and incubated at room temperature for 24 hours. Next, the presence or absence of bacterial growth was determined by measuring the absorbance with a microplate reader, the minimum growth inhibitory concentration (MIC) was determined, and the fractional inhibitory concentration index (FI and index) was calculated according to my own equation. : FIC index
  • the external preparation for skin of the present invention has high antibacterial properties against skin resident bacteria. It is safe and does not cause side effects. Therefore, the external preparation for skin of the present invention is used on a daily basis such as cosmetics and toiletries for the prevention of acne, atopic dermatitis, pyoderma, reduction of unpleasant odor, and improvement of the scalp condition. It can be used suitably also for the product used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une préparation externe pour la peau, qui possède une activité anti-bactérienne élevée contre une bactérie qui colonise normalement la surface de la peau. La préparation externe comprend une apolactoferrine. L'apolactoferrine a un degré de liaison au fer de 5 % ou moins. Lorsqu'une solution aqueuse contenant l'apolactoferrine à une concentration de 1 % en poids/volume est préparée, la solution aqueuse a une concentration cationique totale de 5 mmol/l ou moins. La préparation externe possède une activité anti-bactérienne élevée contre les bactéries qui colonisent normalement la surface de la peau, est absolument sans danger, et ne provoque aucun effet secondaire. Par conséquent, la préparation externe peut être utilisée de façon appropriée dans un produit destiné à un usage quotidien, y compris un produit cosmétique et un produit de toilette.
PCT/JP2007/068013 2006-09-11 2007-09-10 Préparation externe pour la peau Ceased WO2008032847A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008534418A JPWO2008032847A1 (ja) 2006-09-11 2007-09-10 皮膚外用剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006245157 2006-09-11
JP2006-245157 2006-09-11

Publications (1)

Publication Number Publication Date
WO2008032847A1 true WO2008032847A1 (fr) 2008-03-20

Family

ID=39183895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/068013 Ceased WO2008032847A1 (fr) 2006-09-11 2007-09-10 Préparation externe pour la peau

Country Status (2)

Country Link
JP (1) JPWO2008032847A1 (fr)
WO (1) WO2008032847A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008063303A (ja) * 2006-09-11 2008-03-21 Up Well:Kk 口内清浄剤
EP2692355A1 (fr) 2012-08-01 2014-02-05 Biagio Biancardi Apolactoferrin pour le tratiement des maladies liées à l'accumulation de fer
WO2019059375A1 (fr) * 2017-09-25 2019-03-28 高砂香料工業株式会社 Précurseur de parfum
JP2020094047A (ja) * 2018-12-06 2020-06-18 株式会社Ｎｒｌファーマ 皮膚常在細菌叢改善又は多様化用剤及びそれを含有する組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0459714A (ja) * 1990-06-26 1992-02-26 Morinaga Milk Ind Co Ltd チロシナーゼ活性阻害剤
JPH05320068A (ja) * 1990-06-26 1993-12-03 Morinaga Milk Ind Co Ltd ラクトフェリン分解物を有効成分とする抗菌剤、チロシナーゼ活性阻害剤、及びラクトフェリン分解物を用いる物品の処理方法
JPH0796529A (ja) * 1993-09-29 1995-04-11 Mitsui Petrochem Ind Ltd 熱可塑性エラストマー回転成形体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07196529A (ja) * 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd 創傷治癒剤、化粧料および養毛剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0459714A (ja) * 1990-06-26 1992-02-26 Morinaga Milk Ind Co Ltd チロシナーゼ活性阻害剤
JPH05320068A (ja) * 1990-06-26 1993-12-03 Morinaga Milk Ind Co Ltd ラクトフェリン分解物を有効成分とする抗菌剤、チロシナーゼ活性阻害剤、及びラクトフェリン分解物を用いる物品の処理方法
JPH0796529A (ja) * 1993-09-29 1995-04-11 Mitsui Petrochem Ind Ltd 熱可塑性エラストマー回転成形体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BISHOP J.G. E TAL.: "In vitro growth inhibition of mastitis-causing coliform bacteria by bovine apo-lactoferrin and reversal of inhibition by citrate and highconcentrations of apo-lactoferin", INFECTION AND IMMUNITY, vol. 14, no. 4, 1976, pages 911 - 918, XP003019975 *
BORTNER C.A. ET AL.: "Bactericidal effect of lactoferrin on Legionella pneumophila", INFECTION AND IMMUNITY, vol. 51, no. 2, 1986, pages 373 - 377, XP003019977 *
LEON-SICAIROS N. ET AL.: "Microbicidal action of lactoferrin and lactoferricin and their synergistic effect with metronidazole in Entamoeba histolytica", BIOCHEMISTRY AND CELL BIOLOGY, vol. 84, no. 3, 2006, pages 327 - 336, XP003019978 *
NONNECKE B.J. ET AL.: "Inhibition of mastric bacteria by bovine milk apo-lactoferrin evaluated by in vitro microassay of bacterial growth", JOURNAL OF DAIRY SCIENCE, vol. 67, no. 3, 1984, pages 606 - 613, XP003019976 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008063303A (ja) * 2006-09-11 2008-03-21 Up Well:Kk 口内清浄剤
EP2692355A1 (fr) 2012-08-01 2014-02-05 Biagio Biancardi Apolactoferrin pour le tratiement des maladies liées à l'accumulation de fer
WO2019059375A1 (fr) * 2017-09-25 2019-03-28 高砂香料工業株式会社 Précurseur de parfum
US11802258B2 (en) 2017-09-25 2023-10-31 Takasago International Corporation Perfume precursor
JP2020094047A (ja) * 2018-12-06 2020-06-18 株式会社Ｎｒｌファーマ 皮膚常在細菌叢改善又は多様化用剤及びそれを含有する組成物
JP2024074993A (ja) * 2018-12-06 2024-05-31 株式会社Ｎｒｌファーマ 皮膚常在細菌叢改善又は多様化用剤及びそれを含有する組成物
JP7777176B2 (ja) 2018-12-06 2025-11-27 株式会社Ｎｒｌファーマ 皮膚常在細菌叢改善又は多様化用剤及びそれを含有する組成物

Also Published As

Publication number Publication date
JPWO2008032847A1 (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
JP4731323B2 (ja) 歯周病治療用及び／又は予防用組成物
US20080070875A1 (en) Acne treatment compositions and methods of use
JP7446362B2 (ja) セイヨウノコギリソウフレッシュ植物圧搾汁濃縮物、製造、および使用
KR20110131498A (ko) 패각 또는 패산호로부터 추출한 알카리용액에 은이온을 포함하는 항균제와 이를 포함하여 조성된 조성물.
JPWO2007148739A1 (ja) 植物由来の細胞賦活化剤、抗老化剤及び細胞外マトリックス産生促進剤
ES2670646T3 (es) Utilización de un extracto de lino procedente de la hidrólisis de las proteínas de lino, como agente activo antimicrobiano
JP2021509410A (ja) モリンガ・オレイフェラ種子のタンパク質抽出物の美容的使用
CN102665709A (zh) 皮肤净化复合物,所述复合物的用途,包含所述复合物的化妆品或药物组合物及其使用方法
CN105451751A (zh) 用于去除皮肤角质材料的、含有绿茶乳杆菌的组合物
KR101494661B1 (ko) 흑마늘박 발효물을 포함하는 두피 또는 모발 케어용 조성물 및 그 제조방법
TW202535440A (zh) 含有源自微型藻類的胞外體之組成物、以及使源自該微型藻類的胞外體的穩定性提升之方法
JP2004346045A (ja) 海洋深層水を使用する酒造時に得られる酒粕抽出エキスを有効成分とする化粧料添加剤、入浴剤及び健康食品類
WO2008032847A1 (fr) Préparation externe pour la peau
KR20170019830A (ko) 비누풀, 유카, 퀼라야 추출물이 함유된 천연계면활성제 조성물 및 이를 함유하는 화장료 조성물
KR20160091315A (ko) 다제내성 그램 양성균 항균제 및 외용제
EP4380599A1 (fr) Composition pour la prévention et/ou le traitement de l'acné
JP2009191019A (ja) 皮膚若しくは毛髪用化粧料
JP2014172859A (ja) 化粧料
JP5017531B2 (ja) 口内清浄剤
JP2018154566A (ja) エキス輸送作用を呈する環状ペプチド誘導体
Habibi et al. Effects of free and nano‐encapsulated bovine lactoferrin on the viability and acid production by Streptococcus mutans biofilms
JP2020152723A (ja) 新規な多重機能性ペプチド及びその用途
JP6420896B2 (ja) 粉末酵素製剤及びその製造方法、並びにその用途
CN110831564A (zh) 局部用组合物
JP2004339140A (ja) 皮膚化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07807417

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008534418

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07807417

Country of ref document: EP

Kind code of ref document: A1